Versican in Health and Disease

REFERENCES

• Iozzo R.V. Matrix proteoglycans: from molecular design to cellular function. Annu. Rev. Biochem. 1998; 67: 609–652
   PubMed Web of Science ®Google Scholar
• Rahmani M., Wong B.W., Ang L., Cheung C.C., Carthy J.M., Walinski H., McManus B.M. Versican: signaling to transcriptional control pathways. Can. J. Physiol. Pharmacol. 2006; 84: 77–92
   PubMed Web of Science ®Google Scholar
• Wight T.N. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr. Opin. Cell Biol. 2002; 14: 617–623
   PubMed Web of Science ®Google Scholar
• Naso M.F., Zimmermann D.R., Iozzo R.V. Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J. Biol. Chem. 1994; 269: 32999–33008
   PubMed Web of Science ®Google Scholar
• Schonherr E., Kinsella M.G., Wight T.N. Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch. Biochem. Biophys. 1997; 339: 353–361
   PubMed Web of Science ®Google Scholar
• Shimizu-Hirota R., Sasamura H., Mifune M., Nakaya H., Kuroda M., Hayashi M., Saruta T. Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors. J. Am. Soc. Nephrol. 2001; 12: 2609–2615
   PubMed Web of Science ®Google Scholar
• Rahmani M., Read J.T., Carthy J.M., McDonald P.C., Wong B.W., Esfandiarei M., Si X., Luo H., Rennie P.S., McManus B.M. Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells. J. Biol. Chem. 2005; 280: 13019–13028
   PubMed Web of Science ®Google Scholar
• Yoon H., Liyanarachchi S., Wright F.A., Davuluri R., Lockman J.C., Chapelle A., Pellegata N.S. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc. Natl. Acad. Sci. USA 2002; 99: 15632–15637
   PubMed Web of Science ®Google Scholar
• Willert J., Epping M., Pollack J.R., Brown P.O., Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev. Biol. 2002; 2: 8, doi: 10.1186/ 1471–213X-2-8
   PubMedGoogle Scholar
• Fedtsova N., Perris R., Turner E.E. Sonic hedgehog regulates the position of the trigeminal ganglia. Dev. Biol. 2003; 261: 456–469
   PubMed Web of Science ®Google Scholar
• Theocharis A.D., Tsolakis I., Tzanakakis G.N., Karamanos N.K. Chondroitin sulfate as a key molecule in the development of atherosclerosis and cancer progression. Adv. Pharmacol. 2006; 53: 281–295
   PubMedGoogle Scholar
• Wegrowski Y., Maquart F.X. Chondroitin sulfate proteoglycans in tumor progression. Adv. Pharmacol. 2006; 53: 297–321
   PubMedGoogle Scholar
• Mullor J.L., Sanchez P., Altaba A.R. Pathways and consequences: hedgehog signaling in human disease. Trends Cell Biol. 2002; 12: 562–569
   PubMed Web of Science ®Google Scholar
• Wight T.N., Merrilees M.J. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ. Res. 2004; 94: 1158–1167
   PubMed Web of Science ®Google Scholar
• Wu Y.J., Lapierre D., Wu J., Yee A.J., Yang B.B. The interaction of versican with its binding partners. Cell Res. 2005; 15: 483–494
   PubMed Web of Science ®Google Scholar
• Theocharis A.D., Tsolakis I., Hjerpe A., Karamanos N.K. Human abdominal aortic aneurysm is characterized by decreased versican concentration and specific downregulation of versican isoform V0. Atherosclerosis 2001; 154: 367–376
   PubMed Web of Science ®Google Scholar
• Theocharis A.D., Tsolakis I., Hjerpe A., Karamanos N.K. Versican undergoes specific alterations in the fine molecular structure and organization in human aneurysmal abdominal aortas. Biomed. Chromatogr. 2003; 17: 411–416
   PubMed Web of Science ®Google Scholar
• Ruigrok Y.M., Rinkel G.J., Wijmenga C. The versican gene and the risk of intracranial aneurysms. Stroke 2006; 37: 2372–2374
   PubMed Web of Science ®Google Scholar
• Theocharis A.D., Theocharis D.A., DeLuca G., Hjerpe A., Karamanos N.K. Compositional and structural alterations of chondroitin and dermatan sulfates during the progression of atherosclerosis and aneurysmal dilatation of the human abdominal aorta. Biochimie 2002; 84: 667–674
   PubMed Web of Science ®Google Scholar
• McGee M., Wagner W.D. Chondroitin sulfate anticoagulant activity is linked to water transfer: relevance to proteoglycan structure in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 1921–1927
   PubMed Web of Science ®Google Scholar
• Zheng P.S., Vais D., Lapierre D., Liang Y.Y., Lee V., Yang B.L., Yang B.B. PG-M/versican binds to P-selectin glycoprotein ligand-1 and mediates leukocyte aggregation. J. Cell. Sci. 2004; 117: 5887–5895
   PubMed Web of Science ®Google Scholar
• Merrilees M.J., Lemire J.M., Fischer J.W., Kinsella M.G., Braun K.R., Clowes A.W., Wight T.N. Retrovirally mediated overexpression of versican V3 by arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointima after vascular injury. Circ. Res. 2002; 90: 481–487
   PubMed Web of Science ®Google Scholar
• Huang R., Merrilees M.J., Braun K., Beaumont B., Lemire J., Clowes A.W., Hinek A., Wight T.N. Inhibition of versican synthesis by antisense alters smooth muscle cell phenotype and induces elastic fiber formation in vitro and in neointima after vessel injury. Circ. Res. 2006; 98: 370–377
   PubMed Web of Science ®Google Scholar
• Tsara M.E., Theocharis A.D., Theocharis D.A. Compositional and structural alterations of proteoglycans in human rectum carcinoma with special reference to versican and decorin. Anticancer Res 2002; 22: 2893–2898
   PubMed Web of Science ®Google Scholar
• Theocharis A.D. Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochim. Biophys. Acta 2002; 1588: 165–172
   PubMed Web of Science ®Google Scholar
• Theocharis A.D., Vynios D.H., Papageorgakopoulou N., Skandalis S.S., Theocharis D.A. Altered content, composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int. J. Biochem. Cell Biol. 2003; 35: 376–390
   PubMed Web of Science ®Google Scholar
• Skandalis S.S., Theocharis A.D., Theocharis D.A., Papadas T., Vynios D.H., Papageorgakopoulou N. Matrix proteoglycans are markedly affected in advanced laryngeal squamous cell carcinoma. Biochim. Biophys. Acta 2004; 1689: 152–161
   PubMed Web of Science ®Google Scholar
• Skandalis S.S., Theocharis A.D., Papageorgakopoulou N., Vynios D.H., Theocharis D.A. The increased accumulation of structurally modified versican and decorin is related with the progression of laryngeal cancer. Biochimie 2006; 88: 1135–1143
   PubMed Web of Science ®Google Scholar
• Labropoulou V.T., Theocharis A.D., Ravazoula P., Perimenis P., Hjerpe A., Karamanos N.K., Kalofonos H.P. Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumors. Histopathology 2006; 49: 582–593
   PubMed Web of Science ®Google Scholar
• Skandalis S.S., Kletsas D., Kyriakopoulou D., Stavropoulos M., Theocharis D. The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochim. Biophys. Acta 2006; 1760: 1217–1225
   PubMed Web of Science ®Google Scholar
• Sheng W., Wang G., LaPierre D.P., Wen J., Deng Z., Wong C.K.A., Lee D.Y., Yang B.B. Versican mediates mesenchymal-epithelial transition. Mol. Biol. Cell 2006; 17: 2009–2020
   PubMed Web of Science ®Google Scholar
• Sheng W., Dong H., Lee D.Y., Lu W.Y., Yang B.B. Versican modulates gap junction intercellular communication. J. Cell. Physiol. 2007; 211: 213–219
   PubMed Web of Science ®Google Scholar
• Sheng W., Wang G.Z., Wang Y.L., Liang J., Wen J., Zheng P.S., Wu Y., Lee V., Slingerland J., Dumont D., Yang B.B. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol. Biol. Cell 2005; 16: 1330–1340
   PubMed Web of Science ®Google Scholar
• La Pierre D.P., Lee D.Y., Li S.Z., Xie Y.Z., Zhong L., Sheng W., Deng Z., Yang B.B. The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res. 2007; 67: 4742–4750
   PubMed Web of Science ®Google Scholar
• Zhang Y., Cao L., Yang B.L., Yang B.B. The G3 domain of versican enhances cell proliferation via epidermal growth factor-like motifs. J. Biol. Chem. 1998; 273: 21342–21351
   PubMed Web of Science ®Google Scholar
• Zheng P.S., Wen J., Ang L.C., Sheng W., Vilora-Petit A., Wang Y., Wu Y., Kerbel R.S., Yang B.B. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J. 2004; 18: 754–756
   PubMed Web of Science ®Google Scholar
• Wu Y., Zhang Y., Cao L., Chen L., Lee V., Zheng P.S., Kiani C., Adams M.E., Ang L.C., Paiwand F., Yang B.B. Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J. Biol. Chem. 2001; 276: 14178–14186
   PubMed Web of Science ®Google Scholar
• Wu Y., Chen L., Zheng P.S., Yang B.B. Beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J. Biol. Chem. 2002; 277: 12294–12301
   PubMed Web of Science ®Google Scholar
• Yang B.L., Zhang Y., Cao L., Yang B.B. Cell adhesion and proliferation mediated through the G1 domain of versican. J. Cell. Biochem. 1999; 72: 210–220
   PubMed Web of Science ®Google Scholar
• Cattaruzza S., Schiappacassi M., Ljungberg-Rose A., Spessotto P., Perissinotto D., Morgelin M., Mucignat M.T., Colombatti A., Periis R. Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J. Biol. Chem. 2002; 277: 47626–47635
   PubMed Web of Science ®Google Scholar
• Miguel-Serra L., Serra M., Hernandez D., Domenzain C., Docampo M.J., Rabanal R.M., de Torres I., Wight T.N., Fabra A., Bassols A. V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. Lab. Invest. 2006; 86: 889–901
   PubMed Web of Science ®Google Scholar
• Cattaruzza S., Perris R. Proteoglycan control of cell movement during wound healing and cancer spreading. Matrix Biol 2005; 24: 400–417
   PubMed Web of Science ®Google Scholar
• Wu Y., Sheng W., Chen L., Dong H., Lee V., Lu F., Wong G.S., Lu W.Y., Yang B.B. Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. Mol. Biol. Cell 2004; 15: 2093–2104
   PubMed Web of Science ®Google Scholar
• Xiang Y.Y., Dong H., Wan Y., Li J., Yee A., Yang B.B., Lu W.Y. Versican G3 domain regulates neurite growth and synaptic transmission of hippocampal neurons by activation of epidermal growth factor receptor. J. Biol. Chem. 2006; 281: 19358–19368
   PubMed Web of Science ®Google Scholar